STOCK TITAN

PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics' chief financial officer Pierre Gravier automatically sold 3,494 shares of common stock on July 14, 2026 at $80.35 per share pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a 26,000 RSU grant. After this transaction, he directly holds 83,986 shares, including 162 shares acquired through the employee stock purchase plan.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Gravier Pierre
Role CHIEF FINANCIAL OFFICER
Sold 3,494 shs ($281K)
Type Security Shares Price Value
Sale Common Stock 3,494 $80.35 $281K
Holdings After Transaction: Common Stock — 83,986 shares (Direct)
Footnotes (1)
  1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
Shares sold 3494.0000 shares Automatic sell-to-cover transaction on July 14, 2026
Sale price 80.3500 per share Price for common stock sold in the sell-to-cover transaction
Shares held after transaction 83986.0000 shares Direct holdings by Pierre Gravier after the sale
RSUs vested 6500 RSUs Portion of a July 13, 2023 grant that vested, triggering tax withholding
Original RSU grant 26000 RSUs July 13, 2023 restricted stock unit grant size
ESPP shares acquired 162 shares Common stock acquired under employee stock purchase plan for period ended June 30, 2026
irrevocable sell to cover election financial
"Represents shares automatically sold pursuant to an irrevocable sell to cover election"
RSUs financial
"in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
employee stock purchase plan financial
"Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did PTCT CFO Pierre Gravier report?

PTC Therapeutics CFO Pierre Gravier reported an automatic sale of 3,494 shares of common stock at $80.35 per share. The sale was executed under an irrevocable sell-to-cover election to satisfy tax withholding on vested RSUs.

Was the PTCT CFO’s stock sale discretionary or for tax withholding?

The sale was for tax withholding, not a discretionary trade. Shares were automatically sold under an irrevocable sell-to-cover election to cover tax obligations from the vesting of 6,500 RSUs granted on July 13, 2023.

How many PTCT shares does CFO Pierre Gravier hold after this transaction?

After the transaction, Pierre Gravier directly holds 83,986 shares of PTC Therapeutics common stock. This total includes 162 shares acquired through the company’s employee stock purchase plan for the period ended June 30, 2026.

At what price were the PTC Therapeutics (PTCT) shares sold by the CFO?

The 3,494 shares of PTC Therapeutics common stock were sold at an average price of $80.35 per share. The transactions occurred as automatic sell-to-cover trades to satisfy tax withholding obligations associated with RSU vesting.

What equity awards were involved in the PTCT CFO’s sell-to-cover transaction?

The sell-to-cover transaction related to the vesting of 6,500 RSUs from a 26,000 RSU grant dated July 13, 2023. The automatic sale of 3,494 shares was used to satisfy tax withholding obligations arising from this vesting.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gravier Pierre

(Last)(First)(Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/14/2026S(1)3,494D$80.3583,986(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 6,500 RSUs from a July 13, 2023 grant of 26,000 RSUs
2. Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
/s/ Avraham S. Adler, Attorney-in-Fact07/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)